Fibrosis pulmonar idiopática (FPI)
Disease progression events in trials of nintedanib in patients with idiopathic pulmonary fibrosis
Nathan SD et al.
Effect of nintedanib in subgroups based on combined pulmonary fibrosis and emphysema (CPFE) index at baseline
Cottin V et al.
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and multiple comorbidities
Glaspole I et al.
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: subgroup analyses by TORVAN stage
Torrisi SE et al.
Gene expression profiling in patients with idiopathic pulmonary fibrosis (IPF) in the INMARK trial
Selman M et al.
Gene expression profiling in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil: data from the INSTAGE trial
Bonella F et al.
Association of circulating proteins with death or lung transplant in the IPF-PRO Registry cohort
Todd JL et al.
Relationship between mRNA-microRNA interactions and forced vital capacity in patients with idiopathic pulmonary fibrosis
Noth I et al.
